MoonLake Immunotherapeutics (MLTX) Return on Equity (2021 - 2026)

MoonLake Immunotherapeutics' Return on Equity history runs 6 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 1.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Equity was 0.01% for Q1 2026 at MoonLake Immunotherapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.06% in Q1 2022 to a low of 0.03% in Q2 2022.
• Historically, Return on Equity has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
• The sharpest annual moves came in 2022 and 2023: Return on Equity tumbled 35 bps in 2022, then gained 2 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then surged by 90 bps to 0.0% in 2023, then sank by 193 bps to 0.0% in 2024, then tumbled by 202 bps to 0.01% in 2025, then fell by 20 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.